This report provides all the information you require to better understand Grifols and its partnering interests and activities over the past seven years

Grifols is a top pharmaceutical company based in Barcelona, Spain.

Grifols is a Spanish global pharmaceutical company specialising in the supply of blood plasma products.

Grifols, listed as a big pharma and big biotech company, has announced 4 M&A deals since 2005, with the lead deals being the acquisitions of Tacleris Pharmaceuticals.

Grifols, a global healthcare company, listed as big biotech and big pharma company aims to improve health and well-being of the people.

Grifols, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

It is a rare event to see a multi-billion dollar acquisition take place involving a company outside the bigpharma top 50.

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

STADA is a major global pharmaceutical company offering generics and OTC products.

Novartis AG is discussing swapping its animal health and human vaccines businesses for Merck & Co Inc’s over-the-counter products unit in a deal that could boost earnings at both companies.

Swiss drugmaker Novartis can spend $4-6 billion per year on m&a to strengthen its core pharma, eyecare and generics businesses or its three smaller units, its chief executive officer said in an interview on Sunday.

Grifols will make a major equity investment in Alkahest, and the companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging

Grifols Diagnostic Division acquires Novartis  transfusion diagnostics unit for $1.68 billion.

Grifols, a big pharma company, has entered pharma deals with Aradigm for licensing and options relating to Pulmaquin, Lipoquin and AERx.

Grifols, a big pharma company, has entered into a $41.4 million equity purchase financing deal with Aradigm.

Grifols and Talecris Biotherapeutics Holdings Corporation have signed a “Consent Agreement” with the Staff of the Bureau of Competition of the US Federal Trade Commission (FTC)

Spain’s Grifols has struck a $3.4 billion deal to buy Talecris Biotherapeutics, finally delivering a premium return for the investment groups that backed the Research Triangle Park, NC-based biotech. Read the Grifols / Talecris story at Reuters